TY - JOUR
T1 - Immuno-hyperthermia effected by antibody-conjugated nanoparticles selectively targets and eradicates individual cancer cells
AU - Kagawa, Tetsuya
AU - Matsumi, Yuki
AU - Aono, Hiromichi
AU - Ohara, Toshiaki
AU - Tazawa, Hiroshi
AU - Shigeyasu, Kunitoshi
AU - Yano, Shuuya
AU - Takeda, Sho
AU - Komatsu, Yasuhiro
AU - Hoffman, Robert M.
AU - Fujiwara, Toshiyoshi
AU - Kishimoto, Hiroyuki
N1 - Funding Information:
This work was supported by the Japan Society for the Promotion of Science [JP15K09959]; Japan Society for the Promotion of Science [JP19K07730]. We thank Dr. Takeshi Nagasaka for helpful discussions, and Tae Yamanishi and Tomoko Sueish for their excellent technical support.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Hyperthermia has been used for cancer therapy for a long period of time, but has shown limited clinical efficacy. Induction-heating hyperthermia using the combination of magnetic nanoparticles (MNPs) and an alternating magnetic field (AMF), termed magnetic hyperthermia (MHT), has previously shown efficacy in an orthotopic mouse model of disseminated gastric cancer. In the present study, superparamagnetic iron oxide nanoparticles (SPIONs), a type of MNP, were conjugated with an anti-HER2 antibody, trastuzumab and termed anti-HER2-antibody-linked SPION nanoparticles (anti-HER2 SPIONs). Anti-HER2 SPIONs selectively targeted HER2-expressing cancer cells co-cultured along with normal fibroblasts and HER2-negative cancer cells and caused apoptosis only in the HER2-expressing individual cancer cells. The results of the present study show proof-of-concept of a novel hyperthermia technology, immuno-MHT for selective cancer therapy, that targets individual cancer cells. Abbreviations: AMF: alternating magnetic field; DDW: double distilled water; DMEM: Dulbecco’s Modified Eagle’s; Medium; f: frequency; FBS: fetal bovine serum; FITC: Fluorescein isothiocyanate; GFP: green fluorescent protein; H: amplitude; Hsp: heat shock protein; MHT: magnetic hyperthermia; MNPs: magnetic nanoparticles; PI: propidium iodide; RFP: red fluorescent protein; SPION: superparamagnetic iron oxide (Fe3O4) nanoparticle.
AB - Hyperthermia has been used for cancer therapy for a long period of time, but has shown limited clinical efficacy. Induction-heating hyperthermia using the combination of magnetic nanoparticles (MNPs) and an alternating magnetic field (AMF), termed magnetic hyperthermia (MHT), has previously shown efficacy in an orthotopic mouse model of disseminated gastric cancer. In the present study, superparamagnetic iron oxide nanoparticles (SPIONs), a type of MNP, were conjugated with an anti-HER2 antibody, trastuzumab and termed anti-HER2-antibody-linked SPION nanoparticles (anti-HER2 SPIONs). Anti-HER2 SPIONs selectively targeted HER2-expressing cancer cells co-cultured along with normal fibroblasts and HER2-negative cancer cells and caused apoptosis only in the HER2-expressing individual cancer cells. The results of the present study show proof-of-concept of a novel hyperthermia technology, immuno-MHT for selective cancer therapy, that targets individual cancer cells. Abbreviations: AMF: alternating magnetic field; DDW: double distilled water; DMEM: Dulbecco’s Modified Eagle’s; Medium; f: frequency; FBS: fetal bovine serum; FITC: Fluorescein isothiocyanate; GFP: green fluorescent protein; H: amplitude; Hsp: heat shock protein; MHT: magnetic hyperthermia; MNPs: magnetic nanoparticles; PI: propidium iodide; RFP: red fluorescent protein; SPION: superparamagnetic iron oxide (Fe3O4) nanoparticle.
KW - Hyperthermia
KW - cancer cells
KW - immuno targeting
KW - magnetic nanoparticles
KW - selective eradication
UR - http://www.scopus.com/inward/record.url?scp=85108648210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108648210&partnerID=8YFLogxK
U2 - 10.1080/15384101.2021.1915604
DO - 10.1080/15384101.2021.1915604
M3 - Article
C2 - 34148497
AN - SCOPUS:85108648210
SN - 1538-4101
VL - 20
SP - 1221
EP - 1230
JO - Cell Cycle
JF - Cell Cycle
IS - 13
ER -
